Kyntra Bio (KYNB) Net Equity Issued and Repurchased (2014 - 2024)

Kyntra Bio has reported Net Equity Issued and Repurchased for 11 years, with the latest figure at $23000.0 in Q4 2024.

• Quarterly Net Equity Issued and Repurchased fell 48.89% year-over-year to $23000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2025 was $23000.0 (down 83.45% YoY) and the FY2024 annual result came in at $139000.0, down 96.27% from the prior year.
• Net Equity Issued and Repurchased eased to $23000.0 in Q4 2024 per KYNB's latest filing, from $116000.0 in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $17.3 million in Q2 2023 and troughed at $23000.0 in Q4 2024.
• A 5-year average of $4.3 million and a median of $1.2 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2023 and 2024: Net Equity Issued and Repurchased surged 566.41% in 2023, then plunged 99.33% in 2024.
• Over 5 years, Net Equity Issued and Repurchased stood at $11.6 million in 2020, then tumbled by 92.76% to $838000.0 in 2021, then soared by 42.6% to $1.2 million in 2022, then plunged by 96.23% to $45000.0 in 2023, then plunged by 48.89% to $23000.0 in 2024.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $23000.0, $116000.0, and $45000.0 for Q4 2024, Q2 2024, and Q4 2023 respectively.